This is the authors' abstract. We don't add key points for this paper.
GLP-1 receptor (GLP-1R) and neuropeptide Y 2 receptor (Y 2 R) dual agonists have shown great potential to treat obesity and type 2 diabetes (T2DM). We developed a multitarget strategy to design monomeric agonists based on Xenopus GLP-1 (xGLP-1) and PYY 3–36 analogues with dual activation activities on GLP-1R and Y 2 R. A novel peptide, 6q, was obtained via stepwise structure optimization and in vitro receptor screens. In db / db and diet-induced obesity (DIO) mice, 6q produced greater effects on long-term glycemic control and body weight reduction than GLP-1R and Y 2 R monoagonist counterparts. Notably, in high-fat diet-induced nonalcoholic steatohepatitis (NASH) mice, 6q treatment significantly reduced hepatic triglyceride and total cholesterol levels and reversed hepatic steatosis compared with GLP-1R monoagonist (liraglutide) treatment. Collectively, these data support the therapeutic potential of our GLP-1R/Y 2 R dual agonist 6q as a novel antidiabetic, antiobesity, and antisteatotic agent.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: